Ipatasertib

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

Ipatasertib, also known as RG7440, is an experimental cancer drug developed by Roche. It is a small molecule that inhibits AKT, a key protein in the PI3K/AKT pathway that helps cancer cells grow. Ipatasertib was discovered by Genentech in collaboration with Array Biopharma and is in phase III trials for breast cancer. In laboratory studies, it showed activity against all three AKT isoforms (AKT1, AKT2, and AKT3).